CYP2C19 pharmacogenetics in patients undergoing coronary stent placement: Is it time to test everyone?
Catheter Cardiovasc Interv
; 93(7): 1253-1254, 2019 06 01.
Article
en En
| MEDLINE
| ID: mdl-31172678
ABSTRACT
Although there are no current guidelines for when to test patients for CYP2C19 loss of function alleles, the current state of evidence suggests that testing high-risk patients should be considered. Based on this meta-analysis, there is no reduction in major adverse cardiovascular events (MACE) in patients that receive genotype-guided antiplatelet therapy, but there is a significant reduction in MACE when including only patients who present with acute coronary syndromes and a significant reduction in myocardial infarction. Genotype-guided therapy shows promise but requires further study to solidify this approach, and to determine which patients derive the most benefit.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Enfermedad de la Arteria Coronaria
/
Intervención Coronaria Percutánea
Tipo de estudio:
Clinical_trials
/
Guideline
/
Systematic_reviews
Límite:
Humans
Idioma:
En
Revista:
Catheter Cardiovasc Interv
Asunto de la revista:
CARDIOLOGIA
Año:
2019
Tipo del documento:
Article